SecBot SecBot

DRTSW

Alpha Tau Medical Ltd.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. L3· CIK 0001871321 Healthcare & Medical Devices
Warrants of Alpha Tau Medical Ltd. · DRTS stock page →
No price
Market cap
$256.2M
Micro cap
1 year
+214.2%
from $3.81 · Nov 17
30 days
−5.2%
from $12.62
52-week range
$3.47–15.50
−23% from high · low Nov 20
Avg volume 20D
596.5K
Nov 16 spike 2.29M
Short interest
6.1K
≈0.0% of shares · +0.8%
Days to cover
1.0
at average volume
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 4 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 5/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 1 added (0 new), 2 trimmed or exited.

  • Short sellersSTEADY

    Short interest +0.8% to 6.1K shares. 1.0 days to cover, ≈0.0% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT340$1.4K
LMR Partners LLPDOUBLED1,494,631$4.4M
WOLVERINE ASSET MANAGEMENT LLCDOUBLED319,910$943.7K
🔒 Fresh data, subscribers onlyADD
🔒 Fresh data, subscribers onlyTRIM

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 15, 2026 FDA
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median
Sep 30, 2026 Inst.
UBS Group AG · NEAR_EXIT
340 shares ($1.4K)
Jun 30, 2026 Inst.
LMR Partners LLP · DOUBLED
1,494,631 shares ($4.4M)
Jun 3, 2026 SEC
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop and commercialize…
6-K · Impact 7/10
Jun 1, 2026 SEC
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at…
6-K · Impact 7/10
May 18, 2026 SEC
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.7M ($0.12/share)…
6-K · Impact 5/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$166.7K
Next QNoneNoneNo data$333.3K
Current FYNoneNoneNo data$503.3K
Next FYNoneNoneNo data$10.7M

Short side

FINRA· Oct 30, 2026
6,125
shares short
+0.8%
vs prior settlement
1.0
days to cover
≈0.0%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 15, 2026
FDA
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a…
Nov 12, 2026
Press release
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
Oct 29, 2026
Activist
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Oct 22, 2026
Contract
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea...
Oct 19, 2026
FDA
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual…

SecBot reports

14 filings · 9 bullish · 0 bearish · 5 neutral
All DRTSW filing & press-release reports (14)